Online Only Articles

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA
Vol. 100 No. 7 (2015): July, 2015 https://doi.org/10.3324/haematol.2015.126557